特集 神経疾患治療の進歩2019
末梢神経疾患の治療の進歩：2019システマティックレビュー
キーワード:
diabetic neuropathy,
chemotherapy–induced neuropathy,
chronic inflammatory demyelinating polyneuropathy
2020 年 37 巻 5 号 p. 744-746
詳細
2020 年 37 巻 5 号 p. 744-746
Various clinical trials for peripheral neuropathy were published in 2019. Systematic review was performed using terms, “neuropathy”, “peripheral neuropathy”, “treatment” and “clinical trials” with the time lock from January 1, 2019 through December 31, 2019. A total of 19 trials were reviewed in this article on diabetic neuropathy (DPN ; n＝7), chemotherapy–induced peripheral neuropathy (CIPN ; n＝5), carpal tunnel syndrome (n＝4), hereditary ATTR amyloidosis (n＝1), chronic inflammatory demyelinating polyneuropathy (CIDP ; n＝1), and multifocal motor neuropathy (n＝1). For painful DPN, milogabalin, exercise, curcumin, deep tissue laser stimulation, and bio–feedback were found to be effective for pain relief. For CIPN, efficacy of pregabalin and duloxetine was confirmed, but muscle stimulatyion, cryotherapy, and topical agents did not show significant efficacy. For ATTR amyloidosis, a tolcapone trial revealed a short–term efficacy on TTR stabilization. For immune–mediated neuropathies, subcutaneous immunoglobulin as a maintenance therapy for CIDP, and multifocal motor neuropath were published. These results showed sustained research activity to develop new therapies for a number of peripheral nerve disorders.
